+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pediatric Vaccines Market, Share, Global Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis

  • ID: 5521690
  • Report
  • January 2022
  • Region: Global
  • 150 Pages
  • Renub Research

FEATURED COMPANIES

  • CSL Limited
  • GlaxoSmithKline, Plc
  • Merck & Co.
  • Pfizer, Inc.’s
  • Sanofi Pasteur’s
Global Pediatric Vaccines Market is expected to reach USD 62 Billion in 2027. In this huge market of vaccines Pediatric Vaccines for Coronavirus account for a significant market share. Over the years, Pediatric vaccination has made a tremendous public health success story. The lives of billions of children have been saved, and millions have the chance of a longer, healthier life, a more significant opportunity to learn, play, read and write, and move around freely without suffering. Besides, in the 21st century, the development, licensing, and implementation of Pediatric vaccines as part of large, systematic immunization programs have also addressed global health inequities. Therefore, imagining a world without vaccines would be life-threatening, with diseases presenting daily risk.



Impact of COVID-19 on Global Pediatric Vaccines Market


With the emergence of the SARS-CoV-2 virus in December 2019 and its potential for global dissemination to cause COVID-19 disease was realized, there was an urgent need to develop vaccines at an unprecedented rate and scale for the particular pandemic. Hence, amidst the pandemic, the global market for Pediatric vaccines declined in 2020 as most of the healthcares personal were busy in COVID-19 management.

However, the Pediatric vaccines market size has shown tremendous growth for the year 2021. All thanks to the COVID-19 vaccines approval for children in few western countries. Furthermore, as the publisher appreciates and quantify the health, economic and social benefits of Pediatric vaccines and immunization programs to individuals and society. The endeavours to see the Global Pediatric Vaccine Industry to register a CAGR of 4.4% during the forecast period of 2021-2027.

Numbers of Vaccinated Pediatric (Infants) Remains Variable


At the same time, access to Pediatric vaccines that prevent life-threatening infectious diseases remains variable to all infants around the world. Further, to eradicate such problems, numerous individuals and agencies are working hard to address them globally. Recently, the development of safe and efficacious vaccination against diseases that cause substantial morbidity and mortality has been a significant scientific advance. Vaccination, sanitation, and clean drinking water are public health interventions that are undeniably responsible for improved infant health outcomes globally.

For instance, agencies including the United Nations Children's Fund (UNICEF), World Health Organization (WHO), Gavi, The Bill & Melinda Gates Foundation, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Initiative (CEPI), with their multiple funding streams have been instrumental in expanding vaccine benefits to all.

Worldwide Pediatric Vaccines Market Size was US$ 47.8 Billion for 2021


The global pediatric vaccines market is robust and has successfully reached enormous potential. Hence, pediatric vaccines are among tremendous advances in global health and development. Besides, pediatric vaccines have safely reduced the scourge of diseases like Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella, helping children grow up healthy and happy. Remarkably, with immunization efforts worldwide, children can walk, play, dance and learn. Today, vaccines are expected to be one of the most cost-effective means of advancing global welfare.

Major Players in Global Pediatric Vaccines Market


The Pediatric vaccines market consists of several major players, including GlaxoSmithKline, Merck & Co, Sanofi Pasteur's, Pfizer, Inc. and Thoracic Aortic Aneurysm (TAA)CSL Limited. Notwithstanding, the key players of pediatric vaccines are broad and far-reaching, though not consistently quantifiable, analyzed or communicated. However, an increasing appreciation for vaccines' economic and social effects is being included in the development of the new vaccine, potentially realizing a more significant benefit to society and resulting in broader implementation by the companies.

This latest report “Pediatric Vaccines Market, Global Forecast By Disease Wise (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella), Crop (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella), Products and Pipeline (GSK Vaccine Product Pipeline, Merck Vaccine Product Pipeline, Sanofi Vaccine Product Pipeline and Pfizer Vaccine Product Pipeline), Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), Key Players Sales (GlaxoSmithKline, Merck & Co, Sanofi Pasteur's, Pfizer, Inc. and Thoracic Aortic Aneurysm (TAA)CSL Limited)” provides a detailed analysis of Pediatric Vaccines Industry.

Disease wise - Pediatric (Infants) Vaccines Market have been covered from 12 viewpoints:


1. Coronavirus (COVID-19)
2. Influenza
3. MMR (Measles, Mumps, and Rubella Vaccine)
4. Pneumococcal
5. Meningococcal
6. Hepatitis
7. DTaP
8. Haemophilus Influenzae Type B (HIB)
9. Combos (Combination)
10. Polio
11. Rotavirus
12. Varicella

Disease wise - Numbers of Vaccinated Pediatric (Infants) have been covered from 12 viewpoints:


1. Coronavirus (COVID-19)
2. Influenza
3. MMR (Measles, Mumps, and Rubella Vaccine)
4. Pneumococcal
5. Meningococcal
6. Hepatitis
7. DTaP
8. Haemophilus Influenzae Type B (HIB)
9. Combos (Combination)
10. Polio
11. Rotavirus
12. Varicella

By Regions - Pediatric (Infants) Vaccines Market and Number have been covered from 5 viewpoints:


1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East and Africa

Vaccines - Products and Pipeline have been covered from 4 viewpoints:


1. GSK Vaccine Product Pipeline
2. Merck Vaccine Product Pipeline
3. Sanofi Vaccine Product Pipeline
4. Pfizer Vaccine Product Pipeline

Company Insight:

  • Overview
  • Recent Development
  • Sales Analysis

Vaccines Key Players Sales have been covered from 5 viewpoints:


1. GlaxoSmithKline, Plc
2. Merck & Co.
3. Sanofi Pasteur's
4. Pfizer, Inc.'s
5. CSL Limited
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • CSL Limited
  • GlaxoSmithKline, Plc
  • Merck & Co.
  • Pfizer, Inc.’s
  • Sanofi Pasteur’s
1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Driver
4.2 Challenges

5. Pediatric (Infant) Vaccines Market

6. Pediatric Vaccinated Numbers

7. Market & Numbers Share - Pediatric Vaccine Analysis
7.1 Pediatric Vaccine Market Share
7.2 Pediatric Vaccinated Population Share
7.3 By Regions Market share

8. Disease wise - Pediatric (Infants) Vaccines Market
8.1 Influenza
8.2 MMR (Measles, Mumps, and Rubella Vaccine)
8.3 Pneumococcal
8.4 Meningococcal
8.5 Hepatitis
8.6 DTaP
8.7 Haemophilus Influenzae Type B (HIB)
8.8 Combos (Combination)
8.9 Polio
8.10 Rotavirus
8.11 Varicella

9. Disease wise - Numbers of Vaccinated Pediatric (Infants)
9.1 Influenza
9.2 MMR
9.3 Pneumococcal
9.4 Meningococcal
9.5 Hepatitis
9.6 DTaP
9.7 Hib (Haemophilus Influenzae Type B)
9.8 Combos (Combination Vaccines)
9.9 Polio
9.10 Rotavirus
9.11 Varicella

10. By Region- Pediatric (Infants) Vaccines Market and Number
10.1 North America
10.1.1 Market
10.1.2 Number
10.2 Europe
10.2.1 Market
10.2.2 Number
10.3 Asia Pacific
10.3.1 Market
10.3.2 Number
10.4 Latin America
10.4.1 Market
10.4.2 Number
10.5 Middle East and Africa
10.5.1 Market
10.5.2 Number

11. Mergers and Acquisitions in the Vaccine Industry

12. Vaccines and Regulator’s Interventions
12.1 Making and Meeting Standards of Quality and Safety
12.2 Vaccine Funding

13. Vaccines - Products and Pipeline
13.1 GSK Vaccine Product Pipeline
13.2 Merck Vaccine Product Pipeline
13.3 Sanofi Vaccine Product Pipeline
13.4 Pfizer Vaccine Product Pipeline

14. Porters Five Forces
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes

15. Company Analysis
15.1 GlaxoSmithKline, plc.
15.1.1 Overview
15.1.2 Recent Development
15.1.3 Sales Analysis
15.2 Merck & Co.
15.2.1 Overview
15.2.2 Recent Development
15.2.3 Sales Analysis
15.3 Sanofi Pasteur’s
15.3.1 Overview
15.3.2 Recent Development
15.3.3 Sales Analysis
15.4 Pfizer, Inc.’s
15.4.1 Overview
15.4.2 Recent Development
15.4.3 Sales Analysis
15.5 CSL Limited
15.5.1 Overview
15.5.2 Recent Development
15.5.3 Sales Analysis

List of Figures:
Figure-01: Global Pediatric (Infant) Vaccines Market (Million US$), 2016 - 2021
Figure-02: Global - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2022 - 2027
Figure-03: Global - Pediatric (Infant) Vaccines Number (Million), 2016 - 2021
Figure-04: Global - Forecast for Pediatric (Infant) Vaccines Number (Million), 2022 - 2027
Figure-05: Disease wise - Influenza Market (Million US$), 2016 - 2021
Figure-06: Disease wise - Forecast for Influenza Market (Million US$), 2022 - 2027
Figure-07: Disease wise - MMR (Measles, Mumps, and Rubella Vaccine) Market (Million US$), 2016 - 2021
Figure-08: Disease wise - Forecast for MMR (Measles, Mumps, and Rubella Vaccine) Market (Million US$), 2022 - 2027
Figure-09: Disease wise - Pneumococcal Market (Million US$), 2016 - 2021
Figure-10: Disease wise - Forecast for Pneumococcal Market (Million US$), 2022 - 2027
Figure-11: Disease wise - Meningococcal Market (Million US$), 2016 - 2021
Figure-12: Disease wise - Forecast for Meningococcal Market (Million US$), 2022 - 2027
Figure-13: Disease wise - Hepatitis Market (Million US$), 2016 - 2021
Figure-14: Disease wise - Forecast for Hepatitis Market (Million US$), 2022 - 2027
Figure-15: Disease wise - DTaP Market (Million US$), 2016 - 2021
Figure-16: Disease wise - Forecast for DTaP Market (Million US$), 2022 - 2027
Figure-17: Disease wise - Haemophilus Influenzae Type B (HIB) Market (Million US$), 2016 - 2021
Figure-18: Disease wise - Forecast for Haemophilus Influenzae Type B (HIB) Market (Million US$), 2022 - 2027
Figure-19: Disease wise - Combos (Combination) Market (Million US$), 2016 - 2021
Figure-20: Disease wise - Forecast for Combos (Combination) Market (Million US$), 2022 - 2027
Figure-21: Disease wise - Polio Market (Million US$), 2016 - 2021
Figure-22: Disease wise - Forecast for Polio Market (Million US$), 2022 - 2027
Figure-23: Disease wise - Rotavirus Market (Million US$), 2016 - 2021
Figure-24: Disease wise - Forecast for Rotavirus Market (Million US$), 2022 - 2027
Figure-25: Disease wise - Varicella Market (Million US$), 2016 - 2021
Figure-26: Disease wise - Forecast for Varicella Market (Million US$), 2022 - 2027
Figure-27: Disease wise - Influenza Number (Million), 2016 - 2021
Figure-28: Disease wise - Forecast for Influenza Number (Million), 2022 - 2027
Figure-29: Disease wise - MMR Number (Million), 2016 - 2021
Figure-30: Disease wise - Forecast for MMR Number (Million), 2022 - 2027
Figure-31: Disease wise - Pneumococcal Number (Million), 2016 - 2021
Figure-32: Disease wise - Forecast for Pneumococcal Number (Million), 2022 - 2027
Figure-33: Disease wise - Meningococcal Number (Million), 2016 - 2021
Figure-34: Disease wise - Forecast for Meningococcal Number (Million), 2022 - 2027
Figure-35: Disease wise - Hepatitis Number (Million), 2016 - 2021
Figure-36: Disease wise - Forecast for Hepatitis Number (Million), 2022 - 2027
Figure-37: Disease wise - DTaP Number (Million), 2016 - 2021
Figure-38: Disease wise - Forecast for DTaP Number (Million), 2022 - 2027
Figure-39: Disease wise - Hib (Haemophilus Influenzae Type B) Number (Million), 2016 - 2021
Figure-40: Disease wise - Forecast for Hib (Haemophilus Influenzae Type B) Number (Million), 2022 - 2027
Figure-41: Disease wise - Combos (Combination Vaccines) Number (Million), 2016 - 2021
Figure-42: Disease wise - Forecast for Combos (Combination Vaccines) Number (Million), 2022 - 2027
Figure-43: Disease wise - Polio Number (Million), 2016 - 2021
Figure-44: Disease wise - Forecast for Polio Number (Million), 2022 - 2027
Figure-45: Disease wise - Rotavirus Number (Million), 2016 - 2021
Figure-46: Disease wise - Forecast for Rotavirus Number (Million), 2022 - 2027
Figure-47: Disease wise - Varicella Number (Million), 2016 - 2021
Figure-48: Disease wise - Forecast for Varicella Number (Million), 2022 - 2027
Figure-49: GlaxoSmithKline, plc.’s Vaccines Sales - Global Revenue (Million US$), 2016 - 2021
Figure-50: GlaxoSmithKline, plc.’s Vaccines Sales - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure-51: Merck & Co. Vaccines Sales - Global Revenue (Million US$), 2016 - 2021
Figure-52: Merck & Co. Vaccines Sales - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure-53: Sanofi Pasteur’s Vaccines Sales - Global Revenue (Million US$), 2016 - 2021
Figure-54: Sanofi Pasteur’s Vaccines Sales - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure-55: Pfizer, Inc.’s Vaccines Sales - Global Revenue (Million US$), 2016 - 2021
Figure-56: Pfizer, Inc.’s Vaccines Sales - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure-57: Thoracic Aortic Aneurysm (TAA)CSL Limited sales - Global Revenue (Million US$), 2016 - 2021
Figure-58: Thoracic Aortic Aneurysm (TAA)CSL Limited sales - Forecast for Global Revenue (Million US$), 2022 - 2027

List of Tables:
Table-01: Global - Pediatric Vaccines Market Share (Percent), 2016 - 2021
Table-02: Global - Forecast for Pediatric Vaccines Market Share (Percent), 2022 - 2027
Table-03: Global - Pediatric Vaccines Population Share (Percent), 2016 - 2021
Table-04: Global - Forecast for Pediatric Vaccines Population Share (Percent), 2022 - 2027
Note: Product cover images may vary from those shown
  • GlaxoSmithKline, Plc
  • Merck & Co.
  • Sanofi Pasteur’s
  • Pfizer, Inc.’s
  • CSL Limited
Note: Product cover images may vary from those shown

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...